160 related articles for article (PubMed ID: 33942607)
21. The role of Bcl-2 family proteins in chronic lymphocytic leukaemia.
Buggins AG; Pepper CJ
Leuk Res; 2010 Jul; 34(7):837-42. PubMed ID: 20359747
[TBL] [Abstract][Full Text] [Related]
22. Development of Noxa-like BH3 mimetics for apoptosis-based therapeutic strategy in chronic lymphocytic leukemia.
Billard C
Mol Cancer Res; 2012 Jun; 10(6):673-6. PubMed ID: 22466256
[TBL] [Abstract][Full Text] [Related]
23. Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis.
Siegmund B; Welsch J; Loher F; Meinhardt G; Emmerich B; Endres S; Eigler A
Leukemia; 2001 Oct; 15(10):1564-71. PubMed ID: 11587214
[TBL] [Abstract][Full Text] [Related]
24. 2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells.
Steele AJ; Prentice AG; Hoffbrand AV; Yogashangary BC; Hart SM; Lowdell MW; Samuel ER; North JM; Nacheva EP; Chanalaris A; Kottaridis P; Cwynarski K; Wickremasinghe RG
Blood; 2009 Aug; 114(6):1217-25. PubMed ID: 19515722
[TBL] [Abstract][Full Text] [Related]
25. Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance.
Pramil E; Herbi Bastian L; Denèfle T; Nemati F; Xiao M; Lardé E; Maloum K; Roos-Weil D; Chapiro E; Le Garff-Tavernier M; Davi F; Decaudin D; Sarfati M; Nguyen-Khac F; Merle-Béral H; Karoyan P; Susin SA
Blood Adv; 2019 Oct; 3(20):2920-2933. PubMed ID: 31648314
[TBL] [Abstract][Full Text] [Related]
26. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
27. BCL-2 Inhibitors, Present and Future.
Ryan CE; Davids MS
Cancer J; 2019; 25(6):401-409. PubMed ID: 31764121
[TBL] [Abstract][Full Text] [Related]
28. Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor.
Vaisitti T; Gaudino F; Ouk S; Moscvin M; Vitale N; Serra S; Arruga F; Zakrzewski JL; Liou HC; Allan JN; Furman RR; Deaglio S
Haematologica; 2017 Nov; 102(11):1878-1889. PubMed ID: 28860341
[TBL] [Abstract][Full Text] [Related]
29. Thioredoxin prolongs survival of B-type chronic lymphocytic leukemia cells.
Nilsson J; Söderberg O; Nilsson K; Rosén A
Blood; 2000 Feb; 95(4):1420-6. PubMed ID: 10666220
[TBL] [Abstract][Full Text] [Related]
30. Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms.
Zhang W; Pelicano H; Yin R; Zeng J; Wen T; Ding L; Huang R
Mol Med Rep; 2015 Nov; 12(5):7374-88. PubMed ID: 26458979
[TBL] [Abstract][Full Text] [Related]
31. Induction of Ca²+-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction.
Zhong F; Harr MW; Bultynck G; Monaco G; Parys JB; De Smedt H; Rong YP; Molitoris JK; Lam M; Ryder C; Matsuyama S; Distelhorst CW
Blood; 2011 Mar; 117(10):2924-34. PubMed ID: 21193695
[TBL] [Abstract][Full Text] [Related]
32. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL
Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698
[TBL] [Abstract][Full Text] [Related]
33. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines.
Pathan NI; Chu P; Hariharan K; Cheney C; Molina A; Byrd J
Blood; 2008 Feb; 111(3):1594-602. PubMed ID: 18032710
[TBL] [Abstract][Full Text] [Related]
34. The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs.
Paulus A; Masood A; Miller KC; Khan AN; Akhtar D; Advani P; Foran J; Rivera C; Roy V; Colon-Otero G; Chitta K; Chanan-Khan A
Br J Haematol; 2014 Apr; 165(1):78-88. PubMed ID: 24467634
[TBL] [Abstract][Full Text] [Related]
35. A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia.
Zhang LN; Li JY; Xu W
Cancer Gene Ther; 2013 Jan; 20(1):1-7. PubMed ID: 23175245
[TBL] [Abstract][Full Text] [Related]
36. VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia.
Samuel S; Tumilasci VF; Oliere S; Nguyên TL; Shamy A; Bell J; Hiscott J
Mol Ther; 2010 Dec; 18(12):2094-103. PubMed ID: 20842105
[TBL] [Abstract][Full Text] [Related]
37. Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide.
Zolnierczyk JD; Błoński JZ; Robak T; Kiliańska ZM; Wesierska-Gadek J
Ann N Y Acad Sci; 2009 Aug; 1171():124-31. PubMed ID: 19723046
[TBL] [Abstract][Full Text] [Related]
38. Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia.
Billard C
Leukemia; 2012 Sep; 26(9):2032-8. PubMed ID: 22453662
[TBL] [Abstract][Full Text] [Related]
39. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.
Pérez-Galán P; Roué G; López-Guerra M; Nguyen M; Villamor N; Montserrat E; Shore GC; Campo E; Colomer D
Leukemia; 2008 Sep; 22(9):1712-20. PubMed ID: 18596739
[TBL] [Abstract][Full Text] [Related]
40. The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells.
Battle TE; Arbiser J; Frank DA
Blood; 2005 Jul; 106(2):690-7. PubMed ID: 15802533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]